Logo

Boehringer Ingelheim Licenses DoubleTwist s CAT

Jun 20, 2001

NEW YORK, June 20- Boehringer Ingelheim has signed a multi-site license for DoubleTwist’s Clustering and Alignment Tools (CAT), the companies announced Wednesday.

DoubleTwist declined to reveal the financial details of the agreement.

"We chose CAT not only for the quality of the technology, but also because we feel that DoubleTwist as a global company is best positioned to support the discovery efforts of our global research units," Bernd Wetzel, head of corporate division research and nonclinical development at Boehringer Ingelheim, said in a statement.

CAT organizes expressed sequence tags and mRNA sequences into full-length gene sequences, uses statistics to correct sequencing and cloning errors, and isolates and analyzes alternative splice forms.

Currently, over 30 companies subscribe to CAT, including Millenium Pharmaceuticals, Affymetrix, and Bristol-Myers Squibb, Oakland-based DoubleTwist said.   

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.